Despite challenges in sample handling and training, benefits of being in India trump risks - Interview with Tom O'Leary and Larisa Nagra Singh - ICON Clinical Research
Jong Ran Kim is Director of Clinical Operations for North Asia (China, Hong Kong and Korea) at ICON. She has over 15 years of experience in the pharmaceutical, biotechniology, CRO industry as well as scientific research. Jong Ran started her career as a Researcher at Samsung BioResearch Institute and then moved to a biotechnology Company developing oxygen carrier in the blood where she was involved in preclinical and the first human phase 1 studies. She has also worked for Eli Lilly starting at CRA level progressing her career to Clinical Research Manager and then to Quality Manager for Asian operations covering China, Korea, Taiwan and India as well as South East Asia. She has a Masters Degree in Bioscience majoring Genetic Engineering from Korea University.
With the pharma industry’s business model under heavy pressure, transforming the scientific interchange between the lab and the clinic is critical by Michael D. Christel. April 2010 Thought Leaders on this piece include Dr. Cyril Clarke, Cyril Clarke, VP, translational medicine, ICON Development Solutions
This report provides a summary of the workshop entitled “Challenges and Opportunities in Establishing Scientific and Regulatory Standards for Assuring Therapeutic Equivalence of Modified Release Products"
Sally Hannam, John Allinson and Ray Briggs at ICON Development Solutions discuss the approaches and advantages of reducing sample volume in clinical studies
Centre Watch Monthly - In the past decade, the contract research staffing space has undergone a major transformation
Thought Leaders on this piece include Jamal Gasmi, M.D. PH.D. VP and Globla Ongology Therapeutic Area Group Leader, ICON Clinical Research.
Anthony Graziosi
R&D Directions - The global recession is challenging CROs and sponsors to be extra diligent in choosing sites for clinical trials.
No longer solely the domain of major players in the United States and Europe, the pursuit of new and innovative drugs for burgeoning patient populations has blurred lines around the globe. High on the list of new pharma frontiers are South America, the Middle East, and Africa.